Sidley Austin LLP advised Vivo Capital and Novo Holdings A/S as lead investors on the deal, while Davis Polk advised Esco Lifesciences. Vivo Capital and Novo...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here